UAM | UAM_Biblioteca | Unified search engine | Scientific Production Portal | UAM Research Data Repository
Biblos-e Archivo
    • español
    • English
  • English 
    • español
    • English
  • Log in
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search Biblos-e Archivo

Advanced Search

Browse

All of Biblos-e ArchivoCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultiesThis CollectionBy Issue DateAuthorsTitlesSubjectsFaculties

My Account

Log inRegister

Statistics

View Usage Statistics

Help

Information about Biblos-e ArchivoI want to submit my workFrequently Asked Questions

UAM_Biblioteca

View Item 
  •   Biblos-e Archivo
  • 1 - Producción científica en acceso abierto de la UAM
  • Producción científica en acceso abierto de la UAM
  • View Item
  •   Biblos-e Archivo
  • 1 - Producción científica en acceso abierto de la UAM
  • Producción científica en acceso abierto de la UAM
  • View Item

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

Author
García-Alfonso, Pilar; García-Foncillas López, Jesús Migueluntranslated; Provencio Pulla, Marianountranslated; The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
Entity
UAM. Departamento de Medicina
Publisher
Adis Int Ltd
Date
2022-03-01
Citation
Drugs & Aging 38.3 (2021): 219-231
 
 
 
ISSN
1170-229X
Funded by
This study was funded by the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) collaborative group. All medical writing assistance was funded by the Spanish Cooperative TTD and Roche Farma SA
Editor's Version
https://doi.org/10.1007/s40266-021-00834-w
Subjects
Medicina
URI
http://hdl.handle.net/10486/701835
Note
Artículo escrito por un elevado número de autores, sólo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM
Rights
© The Author(s) 2021

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.

Abstract

Background Biologicals, in combination with chemotherapy, are recommended as first-line treatment of metastatic colorectal cancer (mCRC); however, evidence guiding the appropriate management of older patients with mCRC is limited. Objective This study was undertaken to compare the efficacy and safety outcomes in older versus younger patients with mCRC who received first-line biological therapy. Methods This retrospective analysis used pooled data from five trials undertaken by the Spanish Cooperative Group for the Treatment of Digestive Tumours. All were studies of adults with advanced CRC who received first-line treatment with chemotherapy plus bevacizumab, cetuximab or panitumumab, stratified by age (≥ 65 vs. < 65 years). Endpoints included progression-free survival (PFS), overall survival (OS), overall response rate (ORR) and safety. Results In total, 999 patients from five studies were included in the analysis: 480 (48%) were aged ≥ 65 years, and 519 (52%) were aged < 65 years. Median PFS did not differ significantly between patients aged ≥ 65 and < 65 years (9.9 vs. 9.4 months; hazard ratio [HR] 1.01; 95% confidence interval [CI] 0.88–1.17). Median OS was significantly shorter in older than in younger patients (21.3 vs. 25.0 months; HR 1.21; 95% CI 1.04–1.41). There was no significant difference between older and younger patients in ORR (59 vs. 62%). Patients aged ≥ 65 years experienced significantly more treatment-related grade 3 or higher adverse events (61.67%) than did patients aged < 65 years (45.86%). Conclusions Biologicals plus chemotherapy is an effective first-line treatment option for selected patients aged ≥ 65 years with mCRC and has a manageable safety profile and efficacy comparable to that observed in younger patients
Show full item record

Files in this item

Thumbnail
Name
first_garcía_da_2021.pdf
Size
1.068Mb
Format
PDF
Description
Artículo principal
Thumbnail
Name
first_garcía_da_2021_an1.pdf
Size
71.57Kb
Format
PDF
Description
Información suplementaria

Refworks Export

Google™ Scholar:García-Alfonso, Pilar - García-Foncillas López, Jesús Miguel - Provencio Pulla, Mariano - The Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)

This item appears in the following Collection(s)

  • Producción científica en acceso abierto de la UAM [18125]

Related items

Showing items related by title, author, creator and subject.

  • Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced nonesmall-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial 

    Reck, Martin; Schenker, Michael; Lee, Ki Hyeong; Provencio Pulla, MarianoAutoridad UAM; Nishio, Makoto; Lesniewski-Kmak, Krzysztof; Sangha, Randeep; Ahmed, Samreen; Raimbourg, Judith; Feeney, Kynan; Corre, Romain; Franke, Fabio Andre; Richardet, Eduardo; Penrod, John R.; Yuan, Yong; Nathan, Faith E.; Bhagavatheeswaran, Prabhu; DeRosa, Michael; Taylor, Fiona; Lawrance, Rachael; Brahmer, Julie
    2019-06-11
  • KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor 

    Serna-Blasco, R.; Sánchez-Herrero, E.; Sanz-Moreno, S.; Rodriguez-Festa, A.; García-Veros, E.; Casarrubios, M.; Sierra-Rodero, B.; Laza-Briviesca, R.; Cruz-Bermúdez, A.; Mielgo-Rubio, X.; Sánchez-Hernández, A.; Uribelarrea, E. A.; Calvo de Juan, VirginiaAutoridad UAM; Romero, A.; Provencio Pulla, MarianoAutoridad UAM
    2021-10-01
  • Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study 

    Sastre, J.; Provencio Pulla, MarianoAutoridad UAM; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
    2021-04-01
All the documents from Biblos-e Archivo are protected by copyrights. Some rights reserved.
Universidad Autónoma de Madrid. Biblioteca
Contact Us | Send Feedback
We are onFacebookCanal BiblosYouTubeTwitterPinterestWhatsappInstagram

Declaración de accesibilidad

 

 

All the documents from Biblos-e Archivo are protected by copyrights. Some rights reserved.
Universidad Autónoma de Madrid. Biblioteca
Contact Us | Send Feedback
We are onFacebookCanal BiblosYouTubeTwitterPinterestWhatsappInstagram

Declaración de accesibilidad